64
Research Trials
29
Peer-reviewed publications
17
Clinical Conditions

Updated interim data from 54 COPD patients and 135,000 monitored hours, showing cough rates rise in the days before exacerbations and correlate only weakly with CAT scores.

A month of continuous monitoring in stable chronic cough shows that multi-day averaging makes cough frequency a more reliable trial endpoint, allowing smaller studies, and reveals a short-lived Hawthorne effect.

Mixed-methods study in Kampala assessing 48-hour cough frequency monitoring with the Hyfe Research app for TB screening and triage, alongside staff-reported implementation barriers.
21 October 2025 · CHEST 2025

There are no FDA-approved drugs for refractory or unexplained chronic cough. Cough suppression therapy delivered by specialist speech-language pathologists is effective, but there are far too few trained clinicians to meet demand. This single-cohort study tested whether the essential components of cough suppression therapy could be delivered digitally, through an extension of Hyfe’s CoughPro app, with text and video education on cough hypersensitivity and instruction in suppression techniques.
Ten adults with refractory chronic cough completed the four-week program. Cough rate and cough bout rate were monitored continuously from a seven-day baseline through the end of treatment. By week four, the mean hourly cough rate had fallen from 19.1 to 11.1 (a 42% reduction), with a similar drop in cough bouts. The reduction was slightly larger in participants with baseline rates above 10 coughs per hour. Eight of ten participants achieved a clinically meaningful improvement in the Leicester Cough Questionnaire, and median scores rose significantly from 11.4 to 14.3.
The results provide proof of concept that behavioural cough suppression therapy can be delivered as a digital therapeutic, which could greatly widen access to treatment. Combined with objective cough monitoring, the approach may also support motivation and adherence. The authors recommend evaluation in a controlled trial. The work was presented as a late-breaking abstract at CHEST 2025 by Laurie Slovarp, PhD, CCC-SLP, with Hyfe co-authors.
Bring objective cough data to your study. Schedule a meeting →